Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus paclitaxel and carboplatin for platinum-sensitive recurrent ovarian cancer
ChiCTR2100045884Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Zhengzhou University
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The Second Affiliated Hospital of Zhengzhou University. Primary endpoints: Objective response rate and Incidence and severity of adverse events. Started May 2021; status: recruiting.
02
Drugs
anlotinibpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2100045884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045884.